Pfizer’s Diabetes Pill Shows Promising Weight Loss Results Similar To Ozempic
Pfizer’s oral diabetes drug has shown promising results in terms of weight loss, rivaling the highly sought-after drug Ozempic from Novo Nordisk, according to experts. The mid-stage trial involved over 400 adults with Type 2 diabetes who were given Pfizer’s danuglipron twice a day or a placebo pill for approximately four months to assess its effectiveness. The Findings The findings, published in JAMA Network, revealed that every dose of danuglipron led to a reduction in patients’ blood sugar levels at week 16 compared to the placebo. Moreover, the highest doses of the pill, specifically 120 milligrams or 80 milligrams, demonstrated significant weight loss effects in patients at week 16 compared to the placebo. For example, the study indicated that individuals who took the 120-milligram dose of the drug twice daily for 16 weeks experienced an average weight loss of around 10 pounds. These results align closely with the outcomes observed in Novo Nordisk’s semaglutide, marketed as O...